VanishID | $10,000,000 | (Apr 24, 2025)
Coologics | $3,000,000 | (Apr 24, 2025)
Cloud Retail | $3,000,000 | (Apr 24, 2025)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Instrumentl | $55,000,000 | (Apr 24, 2025)
Scamnetic | $13,000,000 | (Apr 24, 2025)
Neurolabs | $7,800,000 | (Apr 24, 2025)
Bloom Credit | $10,500,000 | (Apr 24, 2025)
HelloSky | $5,500,000 | (Apr 24, 2025)
Synthetic Design Lab | $20,000,000 | (Apr 24, 2025)
Hokodo | $11,355,829 | (Apr 24, 2025)
Nourish | $70,000,000 | (Apr 24, 2025)
Alpaca | $52,000,000 | (Apr 24, 2025)